Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 62

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 62
---
 be entitled to receive a one-time grant of 43,860 RSUs in place of $100,000 of her                                 
 Updated Salary in lieu of cash paymentfor such one (1) year period (the “2025 Salary RSUs”) under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Salary RSUs shall vest as follows:                
 provided that Ms. Toledano has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Salary RSUs shall vest over a one (1) year period, with 100% of the 2025 Salary RSUs vesting 
 in four substantially equal portions over the 12 month period following April 1, 2025, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly installment, the number of 2025    
 Salary RSUs that vest in the installment shall be such that Ms. Toledano will be fully vested in the total number of 2025 Salary RSUs listed above as of such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of   
 the 2025 Salary RSUs shall become fully vested on April 1, 2026); provided further, however, that in the event of the Change in Control in which Ms. Toledano continues to provide services to the Company on the date of consummation of such  
 Change in Control, 100% of any unvested 2025 Salary RSUs at the time of the consummation of such Change in Control shall become fully vested.                                                                                                   |

Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 37 Proposal Shareholders are being asked to adopt the following resolution: “RESOLVED, that the revised compensation terms and one-time grant of compensation to Miranda Toledano, our Chief Executive Officer, as described in Proposal Two of the Company’s Proxy Statement for the Company’s 2025 Annual Meeting, be, and are hereby, ratified and approved.” Vote Required Proposal Two requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast “for” than “against” for Proposal Two, and abstentions and broker non-votes have no effect on the outcome of Proposal Two. In addition to the simple majority vote described above, the Israeli Companies Law requires further, to